Full text not available from this repository.

Abstract

Objective: Determine the prevalence of multiple sclerosis (MS) in Australia in 2017 using MS-specific disease-modifying therapy (DMT) prescription data and estimate the change in prevalence from 2010.Methods: DMT prescriptions were extracted from Australia’s Pharmaceutical Benefits Scheme (PBS) data for January-December 2017. Percentages of people with MS using DMTs (DMT penetrance) were calculated using data from the Australian MS Longitudinal Study. Prevalence was estimated by dividing the total number of monthly prescriptions by 12 (except alemtuzumab), adjusted for DMT penetrance and Australian population estimates. Prevalences in Australian states/territories were age-standardised to the Australian population. Comparisons with 2010 prevalence data was performed using Poisson regression.Results: Overall DMT penetrance was 64%, and the number of people with MS in Australia in 2017 was 25,607 (95% CI: 24,874-26,478), a significant increase of 4,324 people since 2010 (pConclusion: Consistent with global trends, Australia’s MS prevalence has increased, this probably reflecting decreased mortality, increased longevity and increased incidence.

Item Type:	Article
Authors/Creators:	Campbell, JA and Simpson Jr, S and Ahmad, H and Taylor, BV and van der Mei, I and Palmer, AJ
Keywords:	Australian Multiple Sclerosis Longitudinal Study, Australian Pharmaceutical Benefits Scheme, immunomodulating agent, health economics
Journal or Publication Title:	Multiple Sclerosis Journal
Publisher:	Sage Publications Ltd
ISSN:	1352-4585
DOI / ID Number:	10.1177/1352458519861270
Copyright Information:	© The Author(s), 2019.
Related URLs:	UTAS Profile: Simpson Jr, S UTAS Profile: Taylor, BV Google Scholar: van der Mei, I UTAS Profile: van der Mei, I UTAS Profile: Palmer, AJ
Item Statistics:	View statistics for this item

Actions (login required)

Item Control Page